Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells.

The activity of small GTP-binding proteins is regulated by a critical step in posttranslational processing, namely, the addition of isoprenoid lipids farnesyl and geranylgeranyl, mediated by the enzymes farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase I), respectively. We have developed compounds that inhibit these enzymes specifically and in this study sought to determine their effects on smooth muscle cells (SMC) from the pulmonary microvasculature. We found that the GGTase I inhibitor GGTI-298 suppressed protein geranylgeranylation and blocked serum-dependent growth as measured by thymidine uptake and cell counts. In the absence of serum, however, GGTI-298 induced apoptosis in these cells as measured by both DNA staining and flow cytometry. The FTase inhibitor FTI-277 selectively inhibited protein farnesylation but had a minor effect on growth and no effect on apoptosis. To further investigate the role of geranylgeranylated proteins in apoptosis, we added the cholesterol synthesis inhibitor lovastatin, which inhibits the biosynthesis of farnesyl and geranylgeranyl pyrophosphates. This also induced apoptosis, but when geranylgeraniol was added to replenish cellular pools of geranylgeranyl pyrophosphate, apoptosis was reduced to baseline. In contrast, farnesol achieved only partial rescue of the cells. These results imply that geranylgeranylated proteins are required for growth and protect SMC against apoptosis. GGTase I inhibitors may be useful in preventing hyperplastic remodeling and may have the potential to induce the apoptotic regression of established vascular lesions.

TGF-beta regulates production of NO in pulmonary artery smooth muscle cells by inhibiting expression of NOS.

We have previously reported that a mixture of lipopolysaccharide and cytokines stimulates cultured rat pulmonary artery smooth muscle cells (RPASM) to express elevated levels of mRNA for inducible nitric oxide synthase (iNOS), and to produce large amounts of nitric oxide (NO). The current study tests the hypothesis that transforming growth factor-beta (TGF-beta) modulates this process. Accordingly, RPASM were treated with a mixture of LPS (10 micrograms/ml) and the cytokines interleukin-1 beta (5 U/ml), tumor necrosis factor-alpha (500 U/ml), and interferon-gamma (100 U/ml). In the absence of TGF-beta 1, NO production (indicated by colorimetric assay of cumulative nitrite levels at 24 h) was greatly increased, as previously observed. Under identical conditions, TGF-beta 1 caused a concentration-dependent decrease in NO production. The addition of neither excess L-arginine nor sepiapterin reversed the inhibition, indicating that the effect of TGF-beta 1 was not due to limitation of enzyme substrate or cofactor tetrahydrobiopterin, respectively. Northern and Western analyses showed that TGF-beta 1 reduced levels of iNOS mRNA and protein to baseline at all time points examined up to 24 h. Complete suppression of iNOS protein expression was evident even when TGF-beta 1 was added at postinduction time points. One mechanism of action of TGF-beta 1 was demonstrated in experiments in which degradation of iNOS protein was greatly increased by the addition of TGF-beta 1. These results demonstrate that TGF-beta 1 regulates production of NO in RPASM by inhibiting iNOS expression in part by increasing degradation of existing iNOS protein.